secwatch.observer — SEC 8-K summary
======================================

Issuer:     RECURSION PHARMACEUTICALS, INC. (RXRX)
CIK:        0001601830
Form:       8-K
Filed at:   2022-06-09T23:59:59+00:00
Accession:  0001193125-22-171124
Event type: leadership
Sentiment:  neutral
Materiality: 0.45
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Recursion Pharmaceuticals: CMO Ramona Doyle departs; Shafique Virani appointed interim CMO
--------------------------------------------------------------------------------

- Ramona Doyle's employment as CMO ended June 7, 2022.
- Shafique Virani appointed interim CMO, effective June 7, 2022.
- Virani continues to serve as chief business officer.
- Virani previously served as interim CMO from March to December 2020.
- Virani joined Recursion in March 2020; prior roles included CEO of BridgeBio subsidiaries.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1601830/000119312522171124/0001193125-22-171124-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1601830/000119312522171124/d272982d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-171124

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer